Clinical resource · Independent · Medically reviewed
Eating well on semaglutide, tirzepatide, and the rest.
GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) reshape how much you eat, what you tolerate, and what your body is doing under the surface. Most generic weight-loss content does not address what changes. GLP-1 Nutrition publishes hedged, dietitian- and physician-reviewed guidance on protein targets, side-effect-friendly meals, muscle-mass preservation, and the calorie- and macro-tracking apps that fit a smaller-meal workflow.
Featured app reviews for GLP-1 users
Editorial assessments scored on fit-for-GLP-1: photo-logging speed when meals are small, protein-tracking depth, micronutrient coverage under reduced intake, and (where applicable) built-in GLP-1 mode.
PlateLens
PlateLens is a photo-first calorie and macronutrient tracker whose feature set — fast photo logging, independently validated calorie accuracy, deep micronutrient coverage, and wearable integrations — fits the smaller-meal, lean-mass-aware tracking pattern that GLP-1 receptor agonist patients commonly need. Editorial pick on the photo-logging axis.
Shotsy
Shotsy is a dedicated GLP-1 dose tracker, not a calorie tracker. Reviewed on its own narrow category. It pairs well with PlateLens, MyNetDiary, or Cronometer for patients who want a clean injection log alongside their nutrition log.
MyNetDiary GLP-1
MyNetDiary's GLP-1 mode is the most-developed dedicated GLP-1 workflow among the apps reviewed. RD-favored on the dedicated-mode reason, with a dietitian-curated database and a functional free tier. Photo logging and UI design are the main weak points.
Cronometer
Cronometer is the strongest hand-tracking option for micronutrient depth among the apps reviewed and remains a defensible pick for GLP-1 patients whose primary nutritional risk concern is deficiency tracking and who are willing to log by typing rather than by photo.
Medications
GLP-1 medication comparison: nutritional impact across the class
Side-by-side comparison of semaglutide, tirzepatide, liraglutide, dulaglutide, and exenatide on the dimensions that matter for nutritional planning. Magnitude of appetite suppression, dose schedule rhythm, side-effect profile, and the practical implications for protein, hydration, and micronutrient planning.
Compounded semaglutide and nutrition: what to know
GLP-1 Nutrition takes no position on whether compounded semaglutide should be used. This article addresses the nutritional considerations that apply to patients who are using compounded formulations, with explicit reminders that compounded medications are not FDA-approved and that all clinical decisions require involvement of a prescribing clinician.
Tirzepatide nutrition guide: Mounjaro and Zepbound
How tirzepatide nutritionally compares with semaglutide. SURMOUNT body-composition findings. Protein, side-effect, hydration, and micronutrient considerations specific to the dual-agonist mechanism.
Protein
Tracking protein when you eat less: the case for visual logging
Why traditional typed food logs become unreliable on GLP-1, and why photo-first logging fits the smaller-meal pattern. Practical comparison with manual tracking. Brief audit periods as an alternative.
Protein and meal-replacement shakes on GLP-1
Liquid protein and meal-replacement shakes on GLP-1 receptor agonist therapy. What to look for in a quality shake. Whey, casein, plant-protein isolate options. Tolerance considerations. Common product categories.
Protein quality and leucine thresholds: the per-meal anabolic signal
Per-meal leucine threshold of approximately 2.5-3 g is the threshold for stimulating muscle protein synthesis. How different protein sources reach (or do not reach) this threshold at different per-meal portions. Practical implications for GLP-1 patients with reduced meal capacity.
Side effects
Dose escalation: side-effect timing and nutritional adjustment
What to expect nutritionally at each dose escalation. The standard adjustment pattern (smaller, lower-fat, more frequent meals; structured hydration; protein-first emphasis). When to discuss titration pace with the clinician.
Gastroparesis considerations on GLP-1: a clinically careful overview
Gastroparesis (delayed gastric emptying) and GLP-1 medications interact in clinically meaningful ways. This article discusses what the published literature describes, what symptoms warrant clinical evaluation, and why nutritional self-management is not appropriate for suspected gastroparesis.
Dehydration and electrolyte attention on GLP-1
Why dehydration is a real risk on GLP-1 even without obvious symptoms. Structured fluid patterns. Electrolyte considerations: sodium, potassium, magnesium. When laboratory monitoring matters.
Muscle mass
Tracking muscle-mass changes on GLP-1: a practical follow-up framework
A practical follow-up framework for tracking muscle-mass changes on GLP-1: body-composition measurement (DXA or BIA), functional measures (grip strength, chair-stand), engagement metrics (protein intake adequacy, resistance-training frequency), and how to interpret the trend with the clinician.
Older adults on GLP-1: sarcopenia risk and muscle-preservation focus
GLP-1 use in older adults is increasing. Higher baseline sarcopenia risk, anabolic resistance, and the consequences of lean-mass loss in this population. Higher protein targets and resistance-training engagement matter more here than in younger patients.
DXA, BIA, and other body-composition tools for GLP-1 follow-up
DXA scans, MRI, bioelectrical impedance (BIA), and anthropometric methods for body-composition tracking on GLP-1. What each measures, what the limitations are, and how to integrate body-composition follow-up with clinical care.
Research
App-assisted GLP-1 nutrition: what the evidence supports
Published evidence on app-assisted nutrition in GLP-1 patient populations. The Tay et al. 2025 trial of dietitian-supported app-based intervention. The Weiss et al. 2026 head-to-head app-accuracy validation study. What the evidence does and does not support.
Long-term GLP-1 discontinuation and rebound: what the data show
STEP-1 Extension trial (Wilding et al., 2022) and SURMOUNT-4 (Aronne et al., 2024) are the most-cited evidence for weight regain after GLP-1 receptor agonist discontinuation. Magnitude of regain. Clinical framing of GLP-1 therapy as long-term. Nutritional implications during and after discontinuation.
Protein and resistance training under hypocaloric conditions: meta-analysis summary
The Sardeli et al. 2018 meta-analysis on resistance training during caloric restriction in obese elderly individuals. The broader literature on protein adequacy under hypocaloric conditions. Translation of pre-GLP-1-era findings to GLP-1-era practice.
Editorial standards
Every clinical guidance article is reviewed by Jonathan Park, MD, FACE, a board-certified endocrinologist. The editorial team is led by Priya Krishnan, MD, ABOM (obesity medicine) and Hannah Ekberg, MS, RD, CDCES (lead dietitian). Read the editorial policy and full medical disclaimer.
GLP-1 Nutrition does not accept payment, affiliate revenue, or sponsorship from medication manufacturers, app developers, or supplement companies. App reviews are funded by editorial budget only.